BACKGROUND: HER-2/neu immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) results guide breast cancer therapy; however, few studies compared the results and no published studies have correlated them with patient outcome. METHODS AND RESULTS: We compared results, cost, and turnaround time in 117 archival, invasive breast carcinomas and compared 50-month survival in 65 of these cases using commercial HER-2/neu IHC and FISH assays. Twenty-one of 112 FISH (19%) and 33 of 117 IHC cases (28%) were positive. Concordance was high overall (88%; 98 of 112 cases) and in IHC 3+ cases (88%; 14 of 16 cases) but low in IHC 2+ cases (35%; six of 17 cases). Survival correlated with IHC results in 3+ cases (P =.02) and FISH cases with signal ratio greater than 4.0 (P =.03), but not in IHC 2+ cases (P=.7). Cost and turnaround time were greater for FISH. CONCLUSION: IHC is appropriate for initial HER-2/neu assessment; however, patients with tumors scored less than 3+, particularly those interpreted as 2+, would benefit from FISH to more accurately assess HER-2/neu status and avoid inaccurate prognostication and inappropriate treatment.
BACKGROUND:HER-2/neu immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) results guide breast cancer therapy; however, few studies compared the results and no published studies have correlated them with patient outcome. METHODS AND RESULTS: We compared results, cost, and turnaround time in 117 archival, invasive breast carcinomas and compared 50-month survival in 65 of these cases using commercial HER-2/neu IHC and FISH assays. Twenty-one of 112 FISH (19%) and 33 of 117 IHC cases (28%) were positive. Concordance was high overall (88%; 98 of 112 cases) and in IHC 3+ cases (88%; 14 of 16 cases) but low in IHC 2+ cases (35%; six of 17 cases). Survival correlated with IHC results in 3+ cases (P =.02) and FISH cases with signal ratio greater than 4.0 (P =.03), but not in IHC 2+ cases (P=.7). Cost and turnaround time were greater for FISH. CONCLUSION: IHC is appropriate for initial HER-2/neu assessment; however, patients with tumors scored less than 3+, particularly those interpreted as 2+, would benefit from FISH to more accurately assess HER-2/neu status and avoid inaccurate prognostication and inappropriate treatment.
Authors: Raymond Tubbs; James Pettay; Marek Skacel; Richard Powell; Mark Stoler; Patrick Roche; James Hainfeld Journal: Am J Pathol Date: 2002-05 Impact factor: 4.307
Authors: C Schindlbeck; W Janni; N Shabani; A Kornmeier; B Rack; D Rjosk; B Gerber; S Braun; H Sommer; K Friese Journal: J Cancer Res Clin Oncol Date: 2005-05-11 Impact factor: 4.553
Authors: An Sen Tan; Joe Poe Sheng Yeong; Chi Peng Timothy Lai; Chong Hui Clara Ong; Bernett Lee; Jeffrey Chun Tatt Lim; Aye Aye Thike; Jabed Iqbal; Rebecca Alexandra Dent; Elaine Hsuen Lim; Puay Hoon Tan Journal: Virchows Arch Date: 2019-08-12 Impact factor: 4.064
Authors: Maria D Corte; Juan A Rodil; Julio Vázquez; Lucia García; Juan C Rodríguez; Miguel Bongera; José C Fernández; Luis O González; Ma Luz Lamelas; Maite Allende; José L García-Muñiz; Antonio Fueyo; Francisco J Vizoso Journal: J Cancer Res Clin Oncol Date: 2005-11-01 Impact factor: 4.553
Authors: Marek Pruszynski; Eftychia Koumarianou; Ganesan Vaidyanathan; Hilde Revets; Nick Devoogdt; Tony Lahoutte; Michael R Zalutsky Journal: Nucl Med Biol Date: 2012-11-15 Impact factor: 2.408